• Nie Znaleziono Wyników

The Voice of the Editor-in-Chief


Academic year: 2022

Share "The Voice of the Editor-in-Chief"

Pokaż więcej ( Stron)

Pełen tekst



The Voice of the Editor-in-Chief

Traditionally, new clinical guidelines of Diabetes Poland are issued at the beginning of the year. The current guidelines of our Society, similarly to those developed by other Societies, take into account signi- ficant changes in the philosophy of treatment of type 2 diabetes and individualization of therapy that goes beyond the glucocentric approach. The key issue deter- mining the choice of an antidiabetic drug has become whether the patient is suffering from cardiovascular or kidney disease or not. The preferred drug for treat- ment intensification (add-on to metformin) in patients with these diseases should be a GLP-1 analogue or an SGLT2 inhibitor, as these drugs provide many benefits in the field of cardiovascular and kidney protection, in addition to reducing blood glucose per se.

I would also like to draw your attention to the topics discussed in this issue of “Clinical Diabetology”.

Although more than 3,500 years have passed since the first description of the symptoms of diabetes in the Egyptian papyrus dated to around 1550 BC, diabetes is still an incurable disease and insulin therapy is the most effective method of decreasing blood glucose. Insulin is indispensable in the treatment of type 1 diabetes and is necessary in many cases of type 2 diabetes. Almost 100 years have passed since the discovery and first use of insulin. Behind us are years of research aimed at mi- micking the body’s physiological response to glycemic excursions and optimizing insulin therapy.

Over the last decades, there has been significant progress in devices supporting the treatment of dia- betes, such as more and more technically advanced subcutaneous insulin pumps and continuous glucose

monitoring systems that, on the one hand, improve gly- cemic control, and on the other hand, reduce the risk of hypoglycemic episodes and thus improve the patient’s comfort of life. What is even more important, this also translates into a reduction in the risk of development and progression of chronic vascular complications of diabetes, which are still a key clinical problem of modern diabetology. One of such devices, the FreeStyle LIBRE continuous blood glucose monitoring system, was eva- luated by a remarkable group of experts in the current edition of “Clinical Diabetology”. Worth reading are also two articles providing a theoretical supplement to the discussion on continuous glycemic monitoring systems:

a review paper discussing the measurement of glucose in the interstitial fluid and a report from Diabetes Inno- vations Day, a meeting dedicated to diabetes innovations and their use by physicians and patients that was held on 23–24 November 2018 in Poznan. Another important topic is diabetes occurring in pregnant women and its impact on a child as well as the woman herself and her future risk of developing type 2 diabetes. In this aspect, I encourage you to read an original paper assessing the ef- fect of breastfeeding on carbohydrate metabolism among women with a history of gestational diabetes. A constant element in the development of “Clinical Diabetology” is the publication of articles sent by foreign authors. This issue includes a very interesting article that will expand our knowledge about the diagnosis of type 1 diabetes in India.

At the end, I would like to thank you for all the articles sent to us and encourage you to further coope- ration. See you in Lublin at the 20th Scientific Congress of Diabetes Poland.


Prof. Janusz Gumprecht

Dear Colleagues,



Powiązane dokumenty

Przekazywał nam też hoj- nie swoje wiadomości, choć byliśmy w wieku, kiedy na ogół nie docenia się wielu skarbów pchających się w ręce.. Na szczęście zapamiętałam zdradzone

„Rodzina w systemie wsparcia społecznego i pomocy osobom z problemem alkoholowym”, zorganizowana przez Pracownię Pedagogiki Specjalnej, w ramach realizowanego

Professor Janusz Gumprecht has excellently developed the journal — it appears regularly, contains more and more papers from outside Poland, is included in the Web of Science

Just before the publication of this issue of “Cli- nical Diabetology”, the largest diabetes meeting in the world — 79 th Scientific Sessions of the American Diabetes

differences in the frequency, causes and duration of hospitalization of children with diabetes in different regions of Poland, which implies the need to ensure uniform access

Another challenge is effective and safe use of antidiabetic drugs to minimize side effects, improve adherence, increase the acceptance of the disease and reduce the risk

At the beginning of October, annual meeting of European Association for the Study of Diabetes (EASD) will be held in Berlin, and one of the most awaited events during this

Among papers included in this issue of “Clinical Diabetology”, it is worth paying attention to a multi- centre study conducted in 2013–2017 in women with type 1 diabetes who,

As the practical management of patients with diabetes should be based primarily on knowledge derived from Evidence Based Medicine (EBM), the reference to the EBM

I would like to draw your attention to the problem of diabetes care quality discussed by researchers from Libya, an interesting case report of the use of hydroxychloroquine in type

Many interesting reports presented during the Congress addressed, among others, epidemiology, new possibilities of molecular biology, measurable effects of translating basic

Both animal models and human studies suggests that altered gut microbiota composition could play a causative role in the development of diabetes type 1, type 2 and

Following the publication of the results of already completed Cardiovascular Outcome Trials (CVOTs) on new molecules used in the treatment of diabetes, there is no doubt that

In the InTandem3 study (Study to Evaluate the Safety of So- tagliflozin in Patients With Type 1 Diabetes Who Have Inadequate Glycaemic Control With Insulin Therapy Alone) with

In addition to attending the scientific meetings, I also encourage you to read the latest issue of the “Clinical Diabetology”, where, among a number of interesting articles, I would

Considering the above, I would like to draw your attention to two of many interesting articles published in the last issue of Clinical Diabetology: the paper presenting

In accordance with other diabetic organizations (the American Diabetes Association — ADA, the National Institute for Health and Care Excellence — NICE), glycaemic goals has

Here, it should be mentioned that also the LEADER trial, that assessed cardiovascular safety of one of GLP-1 agonists, liraglutide, in the population of type 2 diabetes

Despite recent advances in medicine, introduction of new hypoglycaemic drugs and the fact that more than 3.500 years have passed since the earliest known record of diabetes

The conference brought together a group of distinguished lecturers and almost 500 participants — physicians dealing in their everyday practice with carbohydrate

At the same time, we intend to continue the educational function of the journal and we do not want to hinder the access to its content for the readers; therefore, we decided

This change is a result of systematic de- velopment of our journal aiming at further increasing its presence and importance on the international arena and striving to

The average prevalence of diabetes in Poland in the years 2010–2014 amounted to 4.47% (the as- sessment carried out on the basis of the number of people reported to the